RxSight (RXST) Non-Current Deferred Tax Liability (2022 - 2023)
RxSight (RXST) posted Non-Current Deferred Tax Liability of $646000.0 for Q4 2023, down 44.45% on a QoQ basis from $1.2 million in Q4 2022, and down 44.45% year-over-year from $1.2 million in Q4 2022.
RxSight (RXST) Non-Current Deferred Tax Liability (2022 - 2023) Analysis & Trends
RxSight's Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $646000.0 for Q4 2023.
- Quarterly Non-Current Deferred Tax Liability fell 44.45% year-over-year to $646000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $646000.0 (down 44.45% YoY) and the FY2023 annual result came in at $646000.0, down 44.45% from the prior year.
- Non-Current Deferred Tax Liability was $646000.0 for Q4 2023 at RxSight, down from $1.2 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $1.2 million in Q4 2022 and bottomed at $646000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | RxSight | 221.81 Mn | -196.39 Mn | 23.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 646,000.00 |
| Dec 31, 2023 | 646,000.00 |
| Dec 31, 2022 | 1.16 Mn |
| Dec 31, 2022 | 1.16 Mn |